Jump to any asset
849 assets, updated daily
As of September 16, 2026, Boston Scientific Corp. (BSX) trades at $43.87. CleaRank Financial AI rates it Sell with a fair value of $43.87, in line with the current price. Wall Street's consensus target is $60.00 across 31 analysts. RSI at 31 is in neutral territory, and the price is below its 50-day average of $46.92.
Boston Scientific Corp. (BSX)
Boston Scientific Corp. NYSE
$43.87
-1.180 (-2.62%)
At close: Sep 15, 4:00 PM EDT
AI Analyst Consensus
21 / 100
Boston Scientific Corp. (BSX) is currently trading at $43.87, below key moving averages and exhibiting bearish technical momentum. The company's fundamentals show a profit margin of 17.50% and a debt-to-equity ratio of 0.50, which is in line with sector averages. However, recent insider activity reveals a significant net selling trend, with $399.9M in total sales versus $11.1M in total purchases, signaling potential concerns among management. Despite the bearish insider sentiment and technical indicators, Wall Street analysts maintain a largely positive outlook, with a consensus 'Buy' rating and a median price target of $60.00, implying a 36.8% upside. This divergence between insider actions and analyst targets presents a key risk for investors. The company's revenue growth has been around 7.5%, and forward estimates suggest continued moderate growth.
BSX Price Analysis
Market Metrics
Open
$44.32
Day Range
$43.68 to $44.99
Prev Close
$45.05
Volume
16.01M
52-Week Range
$42.20 to $109.50
Market Cap
$63.58B
Peer Benchmarking
Valuation vs Sector (Healthcare)
Performance vs XLV
Sector Position Analysis
Trading at a notable discount to sector peers (-43%), which may indicate undervaluation or specific company headwinds.
BSX Financial Performance
Revenue vs. Earnings
Annual
Quarterly
Earnings Reality Check
Analysis: In the last 5 quarters, BSX beat estimates 4 times. However, the stock fell 2 times the next day. This suggests positive news is often "priced in" or investors are selling the news.
BSX Analysis
Company's Health
3/5
AI Technical Analysis
Boston Scientific Corp. (BSX) is trading below its 50-day and 200-day moving averages ($46.92 and $65.14), indicating a bearish trend. The 50-day SMA is at $46.92 and the 200-day SMA is at $65.14, with the current price of $43.87 falling below both. The Relative Strength Index (RSI) is at 30.89, classified as 'BEARISH', suggesting weakening momentum. The MACD is also negative at -1.16, reinforcing the bearish technical picture. Volume has been below average recently, with the latest volume at 16.01 million compared to an average of 19.75 million. Key support levels are being tested, and the current price action suggests further downside potential if these levels break. The bearish RSI and MACD, coupled with the price being below critical moving averages, point towards continued weakness in the near term. Investors should monitor volume for any signs of capitulation or renewed buying interest, but the current technical setup is unfavorable.
ProTips
- Monitor insider transactions closely; the current heavy selling trend is a significant bearish signal that warrants caution.
- Given the bearish technicals, consider waiting for a confirmed break above the 50-day SMA ($46.92) before considering new long positions.
- The divergence between Wall Street's optimistic price targets and insider selling presents a key risk; ensure any investment aligns with your risk tolerance.
Key Catalysts
Bearish
Heavy Insider Selling Pressure
Insiders have sold over $107.9 million worth of BSX stock versus only $10 million in purchases, indicating a strong heavy insider selling and potentially signaling management's lack of confidence in near-term prospects.
Source: Insider TransactionsBearish
Bearish Technical Momentum
The stock is trading below its 50-day and 200-day moving averages ($46.92 and $65.14), with a bearish RSI (30.89), suggesting continued downside potential.
Source: Technical AnalysisBullish
Consistent Earnings Beats
Boston Scientific has a track record of beating EPS estimates, most recently by 3.61% for the quarter ending June 2026, which could provide underlying support if sustained.
Source: Earnings ReportsBullish
Positive Analyst Price Targets
The median analyst price target of $60.00 implies a 36.8% upside from the current price, suggesting Wall Street sees potential for recovery and growth.
Source: Wall Street AnalystsMarket Outlook
The base case for Boston Scientific Corp. (BSX) over the next 6-12 months appears challenging, given the strong bearish signals from insider activity and technical indicators. While analysts have a median price target of $60.00, implying significant upside, the current price action and heavy insider selling suggest these targets may be difficult to achieve in the near term. The stock's position below key moving averages and a bearish RSI indicate potential for further declines. Factors that could alter this outlook include a significant shift in insider sentiment, a strong earnings beat with positive forward guidance, or a successful new product launch that revitalizes growth. Conversely, continued insider selling, a failure to meet earnings expectations, or increased competitive pressure could exacerbate the bearish trend and push the stock towards its lower support levels or even the downside projection of $27.82 from the long-range forecast.
Key Statistics
| Market Cap | 63.58B |
|---|---|
| P/E Ratio | 18.10 |
| EPS (TTM) | 2.47 |
| Dividend Yield | 0.00% |
| 52 Week High | 109.50 |
| 52 Week Low | 42.20 |
Boston Scientific Corp. (BSX) exhibits a mixed fundamental picture, with a Price-to-Earnings (P/E) ratio of 18.10 and a Price-to-Sales (P/S) ratio of 3.09. These valuations appear reasonable when compared to sector averages, where the median P/E is 31.9 and P/S is 3.7. The company's return on equity stands at a healthy 15.34%, and its profit margin is 17.50%, both exceeding sector medians. The debt-to-equity ratio of 0.50 is also in line with the sector average. However, the company's growth trajectory is moderating, with revenue growth reported at 7.5% and forward estimates for next year's revenue growth at 5.00%. While profitability metrics are strong, the current valuation does not appear significantly undervalued given the slowing growth and substantial insider selling. The company's ability to maintain its growth and profitability in a competitive medical device market will be key to future performance.
Earnings & Growth Analysis
Boston Scientific Corp. (BSX) most recently reported earnings for the quarter ending June 2026, with an actual EPS of $0.86, beating the estimate of $0.83 by 3.61%. This earnings beat was accompanied by a slight price decrease of -0.09%. Prior quarters have also shown consistent EPS beats, though the price reaction has varied, including a -1.41% drop following the September 2025 quarter's beat. The company's earnings performance has been solid, consistently meeting or exceeding analyst expectations.
Key Risks
The primary risk for Boston Scientific Corp. (BSX) stems from significant insider selling, with over $107.9 million in sales against $10 million in purchases, indicating a heavy insider selling. This heavy selling pressure from management and key personnel suggests a lack of confidence in near-term prospects, despite positive analyst ratings. Additionally, the stock is trading below its key 50-day and 200-day moving averages, with a bearish RSI, indicating a weak technical outlook that could lead to further price declines. Competition within the medical device sector also presents an ongoing challenge.
Technical Indicators
| RSI (14) | 30.89 |
|---|---|
| MACD | -1.16 |
| SMA 50 | 46.92 |
| SMA 200 | 65.14 |
RSI
Bearish
SMA Cross
Bearish
Price vs SMA
Bearish
MACD
Bearish
Moving averages show a lagging Death Cross (50-day: $46.92, 200-day: $65.14), price is trading below the 50-day SMA.
Market Correlations
How this stock moves relative to other assets
Based on 1 year of daily price data. Correlations may vary over different time periods.
S&P 500 (SPY)
+0.29
Weak correlation
Nasdaq 100 (QQQ)
+0.23
Weak correlation
Bitcoin (BTC)
+0.08
Weak correlation
Gold (XAU)
+0.04
Weak correlation
Check Custom Correlation
How does any other asset move with BSX? One year of daily closes, Pearson correlation.
Try
BSX Trade Plans
Specific entry, exit, and risk management levels
Select Your Trade Bias
Risk Tolerance
Conservative
2%
Aggressive
Portfolio Value
$
Position Size: Enter portfolio size →
Short entry pick an entry style
Conservative
$44.75
2% above current price
Lower risk, wait for rally
Aggressive
$43.87
Short at current price
Higher risk, chasing the move
Risk Management
STOP LOSS
$46.76
MAX LOSS
-4.5%
Volatility-Adjusted Stop Loss
Calculated based on RSI (30.9) and current market volatility
Profit Targets (Based on Conservative Entry)
TARGET 1
$42.51
-5% (Conservative)
-3.1% (Aggressive)
TARGET 2
$40.27
-10% (Conservative)
-8.2% (Aggressive)
TARGET 3
$38.04
-15% (Conservative)
-13.3% (Aggressive)
Consider scaling out: Take 50% profit at Target 1, 30% at Target 2, let 20% run to Target 3
Calculate Your Trade
Disclaimer
This AI-generated trade plan for BSX is for educational and informational purposes only and does not constitute financial advice. The analysis is based on historical data patterns and technical indicators which may not predict future results. Stock trading involves risk of loss. Verify all data independently and consult a qualified financial advisor. Generated on September 16, 2026.Growth of $10,000
A $10,000 investment in BSX in September 2016 would be worth about $18,668 today, compared with about $35,497 for the same investment in the S&P 500 benchmark.
Compare with Another Ticker
Monte Carlo Projection (10yr)
CleaRank's 10-year Monte Carlo simulation projects that a $10,000 investment in BSX today could grow to about $19,297 by 2036 in the base case, with a bull case near $60,084 and a bear case around $6,198. Projections are statistical simulations, not guarantees.
BSX Stock Price Prediction: 2030
CleaRank's simulation projects a price near $57.06 for BSX by 2030 in the base case, from $43.87 today (1.3x over 4 years). The downside path ends near $27.82. These are outcomes of a Monte Carlo simulation run on BSX's historical return distribution, not price targets, and they assume no dividends are reinvested.
| Year | Downside (10th pct) | Base case | Upside (90th pct) |
|---|---|---|---|
| 2027 | $32.71 | $46.85 | $67.10 |
| 2028 | $30.11 | $50.03 | $83.15 |
| 2029 | $28.68 | $53.43 | $99.54 |
| 2030 | $27.82 | $57.06 | $117 |
| 2031 | $27.30 | $60.94 | $136 |
| 2032 | $27.00 | $65.08 | $157 |
| 2033 | $26.87 | $69.50 | $180 |
| 2034 | $26.88 | $74.23 | $205 |
| 2035 | $26.99 | $79.27 | $233 |
| 2036 | $27.19 | $84.66 | $264 |
Method: 10,000 simulated price paths using BSX's historical volatility and drift, re-run daily. The base case is the median path; the two outer columns are the 10th and 90th percentile outcomes, which widen with time because uncertainty compounds. Simulations are not guarantees, and past volatility does not predict future returns. This is analysis, not investment advice.
People Also Watch
BSX Insider Trading Analysis
Bought
$10.0M
8 Transactions
Sold
$107.9M
22 Transactions
Insiders
19
Active Traders
Avg Transaction
$3.9M
Large trades
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Jun 2, 2025 | MAHONEY MICHAEL F
Chief Executive Officer
|
Sell | 164.4K | $17.1M |
| May 1, 2025 | MAHONEY MICHAEL F
Chief Executive Officer
|
Sell | 164.4K | $16.9M |
| Apr 1, 2025 | MAHONEY MICHAEL F
Chief Executive Officer
|
Sell | 164.4K | $16.4M |
| Feb 2, 2026 | MAHONEY MICHAEL F
Chief Executive Officer
|
Sell | 160.9K | $15.0M |
| Nov 5, 2024 | MAHONEY MICHAEL F
Chief Executive Officer
|
Sell | 162.8K | $13.8M |
| Oct 7, 2024 | MAHONEY MICHAEL F
Chief Executive Officer
|
Sell | 162.8K | $13.8M |
| Sep 5, 2024 | MAHONEY MICHAEL F
Chief Executive Officer
|
Sell | 162.8K | $13.2M |
| Oct 7, 2024 | FITZGERALD JOSEPH MICHAEL
Officer
|
Sell | 132.5K | $11.3M |
| Aug 2, 2021 | MAHONEY MICHAEL F
Chief Executive Officer
|
Sell | 201.0K | $9.2M |
| Nov 3, 2020 | MAHONEY MICHAEL F
Chief Executive Officer
|
Sell | 259.2K | $9.1M |
Page 1 of 1
Frequently Asked Questions
Is Boston Scientific Corp. stock a buy right now?
Boston Scientific Corp. (BSX) is currently rated 'Sell' by our AI analysis due to heavy insider selling and bearish technicals, despite a 'Buy' consensus from Wall Street analysts. The current price is $43.87, with a median analyst target of $60.00.
What is Boston Scientific's stock price forecast for 2030?
Based on Monte Carlo simulations, Boston Scientific Corp. (BSX) has a base case forecast of $57.06 for 2030, with a downside projection of $27.82 and an upside projection of $117.04. These are statistical outcomes, not guarantees.
What are the main risks facing Boston Scientific Corp.?
The primary risks include significant insider selling totaling over $107.9 million, a bearish technical outlook with the stock below key moving averages, and intense competition within the medical device industry.
How does Boston Scientific's valuation compare to its peers?
Boston Scientific's P/E ratio of 18.10 and P/S ratio of 3.09 are below the sector medians of 31.9 and 3.7, respectively, suggesting a potentially more attractive valuation on these metrics. Its profit margin of 17.50% also surpasses the sector median of 6.9%.
What was Boston Scientific's most recent earnings performance?
In the quarter ending June 2026, Boston Scientific reported an EPS of $0.86, beating estimates by 3.61%. The stock price saw a slight decrease of -0.09% following this announcement.
What is the Wall Street consensus on Boston Scientific stock?
Wall Street analysts maintain a 'Buy' consensus for Boston Scientific (BSX), with 31 analysts covering the stock. There are 8 'Strong Buy' ratings, 18 'Buy' ratings, and 5 'Hold' ratings, contributing to a Wall Street score of 77 out of 100.
Are there any significant insider transactions for BSX?
Yes, recent insider activity for BSX indicates a heavy insider selling, with total sales amounting to $107.9 million compared to total purchases of $10 million in recent filings.